Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Precision Therapeutics Inc (AIPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,470
  • Shares Outstanding, K 12,992
  • Annual Sales, $ 650 K
  • Annual Income, $ -7,750 K
  • 36-Month Beta 2.14
  • Price/Sales 7.76
  • Price/Cash Flow N/A
  • Price/Book 4.26
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.97
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 04/01/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.83 +14.46%
on 01/16/19
1.15 -17.39%
on 02/05/19
+0.13 (+15.85%)
since 01/15/19
3-Month
0.60 +58.33%
on 01/09/19
1.15 -17.39%
on 02/05/19
+0.12 (+13.77%)
since 11/15/18
52-Week
0.60 +58.33%
on 01/09/19
1.58 -39.87%
on 07/13/18
-0.15 (-13.64%)
since 02/15/18

Most Recent Stories

More News
Precision Therapeutics' Skyline Medical Division Expands Presence in Australia with Three New STREAMWAY Systems at Wangaratta Hospital in Victoria

Precision Therapeutics Inc. (NASDAQ: AIPT) ("Precision" or "the Company") today announces its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY System for automated, direct-to-drain...

AIPT : 0.95 (-1.04%)
SKLN : 1.21 (-11.03%)
Precision Therapeutics' TumorGenesis Division Isolates Discovery Biomarkers for Thyroid Cancer Cell Types, Initiating Its Proprietary Process for New Drug Development Via Patient-Derived Tumor Models

Precision Therapeutics Inc. (NASDAQ: AIPT) ("Precision" or "the Company") today announces its TumorGenesis subsidiary has identified three thyroid cancer cell types and has isolated the discovery biomarkers....

AIPT : 0.95 (-1.04%)
Precision Therapeutics Has Groundbreaking Approach to Personalized Cancer Treatment, Reports CEOCFO Magazine

Precision Therapeutics is offering ''true personalized oncology,'' CEO Dr. Carl Schwartz tells CEOCFO Magazine, thanks to the company's unique database of tumors, artificial intelligence technology, and...

AIPT : 0.95 (-1.04%)
Precision Therapeutics' Skyline Medical Division Significantly Expands Footprint in New England With Sale of Six STREAMWAY Systems to Yale University Ambulatory Outpatient Surgical Center

Precision Therapeutics Inc. (NASDAQ: AIPT) ("Precision" or "the Company") today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY System for automated, direct-to-drain...

AIPT : 0.95 (-1.04%)
SKLN : 1.21 (-11.03%)
Precision Therapeutics Reports Third Quarter 2018 Financial Results

Precision Therapeutics Inc. (NASDAQ: AIPT) ("Precision" or "the Company"), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today financial results...

AIPT : 0.95 (-1.04%)
Helomics Corp Partners with UK 100,000 Genomes Project to Drive its Artificial Intelligence-Powered Precision Oncology Platform for Ovarian Cancer

Helomics will utilize whole genome and outcome data from the U.K. 100,000 Genomes Project to advance its artificial intelligence-based platform for ovarian cancer.

AIPT : 0.95 (-1.04%)
Precision Therapeutics to Hold Business Update Conference Call on November 14, 2018

Precision Therapeutics Inc. (NASDAQ: AIPT) ("Precision" or "the Company"), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management...

AIPT : 0.95 (-1.04%)
Precision Therapeutics Secures Rights to Novel Technology Designed To Develop Drugs That Target Specific Cancer by Its Mutation

Precision Therapeutics Inc. (NASDAQ: AIPT) ("Precision" or "the Company"), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has...

AIPT : 0.95 (-1.04%)
Precision Therapeutics' CEO Talks with Uptick Newswire's Stock Day Podcast About Exciting New Breakthroughs in Tumor Treatment and What's on the Horizon

Precision Therapeutics (Nasdaq: AIPT) (The "Company") is a company applying artificial intelligence to personalized medicine and drug discovery. Their CEO, Dr. Carl Schwartz, and Richard Gabriel, a consultant...

AIPT : 0.95 (-1.04%)
Precision Therapeutics Continues to Build World Class Scientific Advisory Board with Appointment of Hector J. Gomez, MD, PhD

Precision Therapeutics Inc. (NASDAQ: AIPT) ("Precision" or "the Company"), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has appointed Dr. Hector J....

AIPT : 0.95 (-1.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade AIPT with:

Business Summary

Precision Therapeutics Inc. operating business areas includes development of a healthcare CRO which provides personalized medicine solutions for clients in the pharmaceutical, diagnostic and biotech industries as well as production of the FDA-approved STREAMWAY(R) System for automated, direct-to-drain...

See More

Key Turning Points

2nd Resistance Point 1.00
1st Resistance Point 0.98
Last Price 0.95
1st Support Level 0.93
2nd Support Level 0.90

See More

52-Week High 1.58
Fibonacci 61.8% 1.21
Fibonacci 50% 1.09
Fibonacci 38.2% 0.97
Last Price 0.95
52-Week Low 0.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar